AACR 2023 | Phase I trial of ARX517, an anti-PSMA ADC, in mCRPC

Scott Tagawa, FACP, MD, MS, Weill Cornell Medicine, New York, NY, provides an overview of the Phase I dose escalation trial (NCT04662580) of ARX517, an antibody-drug conjugate (ADC) targeting PSMA, in patients with metastatic castration-resistant prostate cancer (mCRPC) resistant or refractory to standard therapies. Dose escalation is continuing, where no dose limiting toxicities at dose level 6 (2.0 mg/kg) were reported. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.